Abstract
Axillary lymph node surgery remains an integral component of breast cancer treatment. Node status provides key prognostic information that is used to direct adjuvant systemic therapy ( 1 ). Removal of the nodes may also improve local control, although the preponderance of data shows no survival advantage with node dissection itself ( 2 ).